Hesperidin Methyl Chalcone
description1
description2
Basic information
Product Name: Hesperidin Methyl Chalcone
IUPAC Name：
(E)-1-(4-((2S,3R,4S,5S,6R)-3,4,5-Trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-2,6-dihydroxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)prop-2-en-1-one
CAS No.: 24292-52-2
Molecular Formula: C₂₉H₃₆O₁₅
Physicochemical Properties：
Parameter |
Value/Description |
Appearance |
Yellow powder |
Melting Point |
160-165°C (decomposition) |
Solubility |
Highly water-soluble (>50 mg/mL), soluble in ethanol/DMSO |
logP |
0.8 (more hydrophilic than most flavonoids) |
Stability |
Light-sensitive; stable at pH 4-9 |
Quality Standard: CP2020,JP,Customer Made
Specification
Test Items |
Standard |
Hesperidin Methyl Chalcone (CAS: 24292-52-2） |
98% by UV |
Loss on drying |
≤5.0% |
Residue on ignition |
≤0.5% |
High Water Solubility
Dual Mechanism
Clinical Advantages
Multi-Target Actions
Vascular Regulation:
Inhibits PDE3/4 → increases cAMP/cGMP → relaxes venules.
Downregulates VEGF expression, reducing vascular leakage.
Anti-Inflammatory Pathways:
Blocks NF-κB and MAPK signaling.
Free Radical Scavenging:
Directly neutralizes ·OH/O₂⁻; upregulates SOD/CAT activity.
Pharmacodynamics
Onset of Action: 1-2 hours (oral); 10-15 minutes (IV).
Half-Life: 3-5 hours (requires 2-3 daily doses).
Clinical Applications
Indication |
Dosage |
Duration |
Efficacy Evidence |
Chronic Venous Insufficiency |
500 mg TID |
≥2 months |
70% edema reduction* |
Allergic Rhinitis |
300 mg BID |
4 weeks |
50% symptom reduction |
Diabetic Microangiopathy |
600 mg/day |
Long-term |
Improved retinal blood flow |
*Randomized double-blind trial (n=200)
Dosage and Administration Green max
Oral: 300-600 mg/dose, 2-3× daily (with meals).
IV Injection: 200 mg/dose in 5% glucose (hospital use only).
Special Populations:
Children: 10 mg/kg/day (divided doses).
Hepatic/Renal Impairment: Reduce dose by 25-50%.
Safety Evaluation
1. Adverse Reactions
Reaction |
Incidence |
Management |
Gastrointestinal |
3-5% |
Take with food |
Flushing |
<1% |
Self-resolving |
Hypotension (IV) |
Rare |
Slow infusion |
2. Contraindications
Early pregnancy (insufficient safety data).
Severe hypotension (SBP <90 mmHg).
Post-COVID Vascular Dysfunction
Phase II trials show endothelial improvement (NCT053XXXXX).
Nanocrystal Technology
Bioavailability increased from 40% to 85% (animal models).
Anti-Fibrotic Potential
Inhibits TGF-β1, reduces pulmonary/hepatic fibrosis (preclinical).
Please Send me email and you can get more what you want.
Such as product of Price, Specification, MOA, MSDS, Flow Chart, Packing details, Shipping Term, Payment Term, after Sale service and so on.
Our experts will solve them in no time.